Patent intelligence · US
US 8377444
Therapeutic agent or preventive agent for osteoarthritis
Therapeutic agent or preventive agent for osteoarthritis
Patent details — US 8377444
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 19, 2013
- Expiration
- Feb 14, 2033
- Applicant
- AXIS
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61P, A61P19/02
Quick answer
US 8377444 (Therapeutic agent or preventive agent for osteoarthritis) is held by AXIS. Status: granted. Granted Feb 19, 2013. Expires Feb 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXIS
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61P, A61P19/02, A61P19/08, A61P29/00
More from AXIS
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 8377444?
US 8377444 (Therapeutic agent or preventive agent for osteoarthritis) is held by AXIS. Status: granted. Granted Feb 19, 2013. Expires Feb 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8377444?
AXIS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 8377444 expire?
Our index shows an expiration date of Feb 14, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.